LINAGLIPTIN AND METFORMIN HYDROCHLORIDE — MSN, approved 2025-11-03 (ANDA208459).
15,280 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.